Evidence map›Paper›PMID 40709544›Full record

ArticleEpilepsia open2025

Redefining drug-resistant epilepsy: Insights from an Italian Delphi consensus study.

Federico Vigevano, Irene Bagnasco, Giancarlo Di Gennaro, Oriano Mecarelli, Simona Lattanzi

Abstract readConsensus Statement
In one paragraph

Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Federico VigevanoHead of Paediatric Neurorehabilitation Department, IRCCS San Raffaele, Rome, Italy.ORCID https://orcid.org/0000-0001-7513-0051
Irene BagnascoChild Neuropsychiatry, Epilepsy Center for Children, Martini Hospital Turin, Turin, Italy.
Giancarlo Di GennaroIRCCS NEUROMED, Pozzilli, Italy.ORCID https://orcid.org/0000-0003-3446-0788
Oriano MecarelliDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Simona LattanziNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.ORCID https://orcid.org/0000-0001-8748-0083

Funding

Angelini Pharma
6 · The paper itself

Abstract

objectiveDrug-resistant epilepsy (DRE) affects approximately one-third of people with epilepsy (PwE) despite advancements in anti-seizure medications and presents significant challenges in epilepsy care. This Delphi consensus study aimed to examine key aspects of DRE, including its definition, predictors, and therapeutic strategies.

methodsA steering committee consisting of clinicians and researchers with expertise in epilepsy was responsible for formulating the statements. A total of 22 statements were developed across four thematic areas. Expert opinions from 99 Italian epileptologists were collected over two structured rounds of voting.

resultsThe study highlighted a certain disagreement on the current International League Against Epilepsy definition of DRE, with experts advocating for a definition that better incorporates individual complexities. Strong agreement emerged on the importance of quality of life, psychiatric comorbidities, and multidimensional care in defining therapeutic success. SIGNIFICANCE: The findings of this study underscored the need for a patient-centered perspective of drug resistance and therapeutic success. Enhancing collaboration across specialties is critical for refining clinical practices and addressing unmet needs for PwE. PLAIN LANGUAGE SUMMARY: About one in three people with epilepsy continues to have seizures despite trying several anti-seizure medications. This study asked Italian epilepsy experts for their opinions on how to define and manage drug-resistant epilepsy. The experts agreed that treatment success should not be measured by seizure control alone but also by improvements in quality of life. They also recommended more personalized care that considers each patient's unique condition.

Indexed as

AnticonvulsantsDrug Resistant EpilepsyDelphi TechniqueHumansItalyQuality of LifeAnticonvulsantsDelphi consensus studydrug‐resistant epilepsy (DRE)epilepsy managementuncontrolled epilepsy

Identifiers

PMID40709544
PMCPMC12514390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.